Literature DB >> 31497220

CD8+ cytotoxic and FoxP3+ regulatory T lymphocytes serve as prognostic factors in breast cancer.

Gong-Ling Peng1, Liang Li2, Ya-Wen Guo3, Pan Yu3, Xing-Jie Yin3, Shan Wang3, Chun-Ping Liu3.   

Abstract

BACKGROUND: There is conflicting evidence regarding the prognostic value of cytotoxic T cell infiltration in breast cancer. The aims of this study were to detect the expression levels and localization of FoxP3 and CD8 in invasive ductal carcinoma of the breast and to investigate the correlations among FoxP3+ regulatory T cells (Tregs), CD8+ cytotoxic T lymphocytes (CTLs), clinicopathological features, and prognosis in patients with breast cancer.
METHODS: Immunohistochemistry was used to detect the expression levels and localization of FoxP3 and CD8. One-sample t-test, one-way analysis of variance, and Kaplan-Meier log-rank tests were used to analyze correlations between the expression levels of CD8 and FoxP3; Kaplan-Meier Log-rank test was used to analyze clinicopathological features to explore the prognostic significance of CD8 and FoxP3 in patients with breast cancer.
RESULTS: FoxP3 expression in the tumor bed was higher than that in the stroma, while CD8 was primarily expressed in the stroma. CD8 expression was associated with favorable prognostic factors. However, FoxP3 expression and an increased ratio of total FoxP3+ Tregs to CD8+ CTLs were significantly correlated with unfavorable prognostic factors. Additionally, an increased ratio was associated with molecular subtypes (ER+Her2+, ER+Her2-, ER-Her2+, and ER-Her2-) of breast cancer. Overexpression of FoxP3 and a high FoxP3+/CD8+ ratio were correlated with poor overall survival (OS) and disease-free survival (DFS). However, CD8 expression only affected OS in patients with breast cancer.
CONCLUSIONS: Tumor-infiltrating lymphocytes are localized variously depending on the subtype. CD8+ CTLs were associated with a good prognosis, while FoxP3+ Tregs were associated with adverse outcomes in patients with breast cancer. CD8+ CTLs and FoxP3+ Tregs are potential predictive prognostic factors for patients with breast cancer.

Entities:  

Keywords:  CD8; FoxP3; breast cancer; tumor bed; tumor stroma

Year:  2019        PMID: 31497220      PMCID: PMC6731430     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  22 in total

Review 1.  The chemokine system in diverse forms of macrophage activation and polarization.

Authors:  Alberto Mantovani; Antonio Sica; Silvano Sozzani; Paola Allavena; Annunciata Vecchi; Massimo Locati
Journal:  Trends Immunol       Date:  2004-12       Impact factor: 16.687

2.  Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.

Authors:  Sahar M A Mahmoud; Emma Claire Paish; Desmond G Powe; R Douglas Macmillan; Matthew J Grainge; Andrew H S Lee; Ian O Ellis; Andrew R Green
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

3.  X-linked lymphoreticular disease in the scurfy (sf) mutant mouse.

Authors:  V L Godfrey; J E Wilkinson; L B Russell
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

4.  Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade.

Authors:  Kristi Baker; Jonathan Lachapelle; Inti Zlobec; Tarek A Bismar; Luigi Terracciano; William D Foulkes
Journal:  Histopathology       Date:  2011-06-24       Impact factor: 5.087

5.  The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3.

Authors:  C L Bennett; J Christie; F Ramsdell; M E Brunkow; P J Ferguson; L Whitesell; T E Kelly; F T Saulsbury; P F Chance; H D Ochs
Journal:  Nat Genet       Date:  2001-01       Impact factor: 38.330

6.  Prognostic value of tumor-infiltrating Foxp3+ T-cell subpopulations in metastatic melanoma.

Authors:  Anne C Knol; Jean M Nguyen; Gaëlle Quéreux; Anabelle Brocard; Amir Khammari; Brigitte Dréno
Journal:  Exp Dermatol       Date:  2011-03-16       Impact factor: 3.960

7.  Analysis of FOXP3 reveals multiple domains required for its function as a transcriptional repressor.

Authors:  Jared E Lopes; Troy R Torgerson; Lisa A Schubert; Stephanie D Anover; Elizabeth L Ocheltree; Hans D Ochs; Steven F Ziegler
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

Review 8.  Tumor-infiltrating T lymphocytes: friends or foes?

Authors:  Ping Yu; Yang-Xin Fu
Journal:  Lab Invest       Date:  2006-03       Impact factor: 5.662

Review 9.  Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation.

Authors:  G Solinas; G Germano; A Mantovani; P Allavena
Journal:  J Leukoc Biol       Date:  2009-09-09       Impact factor: 4.962

10.  Determination of tumor-infiltrating CD8+ lymphocytes in human ovarian cancer.

Authors:  Stefanie Aust; Anna Bachmayr-Heyda; Dietmar Pils; Lijun Zhao; Weimin Tong; Astrid Berger; Mina Fogel; Theresa Thalhammer; Jalid Sehouli; Reinhard Horvat; Robert Zeillinger; Dan C Castillo-Tong
Journal:  Int J Gynecol Pathol       Date:  2013-05       Impact factor: 2.762

View more
  26 in total

1.  Enhancement of antitumor immune response by radiation therapy combined with dual immune checkpoint inhibitor in a metastatic model of HER2-positive murine tumor.

Authors:  Sayaka Misaki; Satoshi Murata; Miyuki Shimoji; Takayasu Iwai; Andreas Michael Sihombing; Ken Aoki; Yutaka Takahashi; Yoshiyuki Watanabe
Journal:  Jpn J Radiol       Date:  2022-06-28       Impact factor: 2.374

2.  CD68 and CD83 immune populations in non-metastatic axillary lymph nodes are of prognostic value for the survival and relapse of breast cancer patients.

Authors:  Carlos López; Ramón Bosch; Anna Korzynska; Marcial García-Rojo; Gloria Bueno; Joan Francesc García-Fontgivell; Salomé Martínez González; Andrea Gras Navarro; Esther Sauras Colón; Júlia Casanova Ribes; Lukasz Roszkowiak; Daniel Mata; Meritxell Arenas; Junior Gómez; Albert Roso; Marta Berenguer; Silvia Reverté-Villarroya; Montserrat Llobera; Jordi Baucells; Marylène Lejeune
Journal:  Breast Cancer       Date:  2022-02-08       Impact factor: 4.239

3.  Role of FoxP3-positive regulatory T-cells in regressive and progressive cervical dysplasia.

Authors:  Linda Hertlein; Thomas Kolben; Aurelia Vattai; Nadine Kremer; Sarah Meister; Susanne Beyer; Lucia Keilmann; Anna Hester; Mina Temelkov; Helene Heidegger; Elisa Schmoeckel; Mirjana Kessler; Sven Mahner; Udo Jeschke
Journal:  J Cancer Res Clin Oncol       Date:  2021-11-05       Impact factor: 4.553

4.  On the Prognostic Power of Tumor-Infiltrating Lymphocytes - A Critical Commentary.

Authors:  Zeev Elkoshi
Journal:  Front Immunol       Date:  2022-05-12       Impact factor: 8.786

5.  Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown.

Authors:  Ying Zhang; Xuemei Xie; Pourya Naderi Yeganeh; Dian-Jang Lee; David Valle-Garcia; Karla F Meza-Sosa; Caroline Junqueira; Jiayu Su; Hongbo R Luo; Winston Hide; Judy Lieberman
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-02       Impact factor: 11.205

Review 6.  Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer.

Authors:  Molly A Nelson; Worapol Ngamcherdtrakul; Shiuh-Wen Luoh; Wassana Yantasee
Journal:  Cancer Metastasis Rev       Date:  2021-05-07       Impact factor: 9.237

7.  Caloric Restriction Impairs Regulatory T cells Within the Tumor Microenvironment After Radiation and Primes Effector T cells.

Authors:  Gregor Manukian; Charles Kivolowitz; Tiziana DeAngelis; Anuradha A Shastri; Jason E Savage; Kevin Camphausen; Ulrich Rodeck; Jelani C Zarif; Nicole L Simone
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-02-26       Impact factor: 8.013

8.  Targeted glycan degradation potentiates the anticancer immune response in vivo.

Authors:  Melissa A Gray; Michal A Stanczak; Natália R Mantuano; Han Xiao; Johan F A Pijnenborg; Stacy A Malaker; Caitlyn L Miller; Payton A Weidenbacher; Julia T Tanzo; Green Ahn; Elliot C Woods; Heinz Läubli; Carolyn R Bertozzi
Journal:  Nat Chem Biol       Date:  2020-08-17       Impact factor: 15.040

9.  Correlations Between the Characteristics of Alternative Splicing Events, Prognosis, and the Immune Microenvironment in Breast Cancer.

Authors:  Youyuan Deng; Hongjun Zhao; Lifen Ye; Zhiya Hu; Kun Fang; Jianguo Wang
Journal:  Front Genet       Date:  2021-06-14       Impact factor: 4.599

Review 10.  Immune System Effects on Breast Cancer.

Authors:  Jensen N Amens; Gökhan Bahçecioglu; Pinar Zorlutuna
Journal:  Cell Mol Bioeng       Date:  2021-06-03       Impact factor: 3.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.